220 related articles for article (PubMed ID: 26805402)
1. The acute and long-term L-DOPA effects are independent from changes in the activity of dorsal raphe serotonergic neurons in 6-OHDA lesioned rats.
Miguelez C; Navailles S; De Deurwaerdère P; Ugedo L
Br J Pharmacol; 2016 Jul; 173(13):2135-46. PubMed ID: 26805402
[TBL] [Abstract][Full Text] [Related]
2. Regulation of dopamine neurotransmission from serotonergic neurons by ectopic expression of the dopamine D2 autoreceptor blocks levodopa-induced dyskinesia.
Sellnow RC; Newman JH; Chambers N; West AR; Steece-Collier K; Sandoval IM; Benskey MJ; Bishop C; Manfredsson FP
Acta Neuropathol Commun; 2019 Jan; 7(1):8. PubMed ID: 30646956
[TBL] [Abstract][Full Text] [Related]
3. L-DOPA elicits non-vesicular releases of serotonin and dopamine in hemiparkinsonian rats in vivo.
Miguelez C; Navailles S; Delaville C; Marquis L; Lagière M; Benazzouz A; Ugedo L; De Deurwaerdère P
Eur Neuropsychopharmacol; 2016 Aug; 26(8):1297-309. PubMed ID: 27234917
[TBL] [Abstract][Full Text] [Related]
4. Increased excitability in serotonin neurons in the dorsal raphe nucleus in the 6-OHDA mouse model of Parkinson's disease.
Prinz A; Selesnew LM; Liss B; Roeper J; Carlsson T
Exp Neurol; 2013 Oct; 248():236-45. PubMed ID: 23810738
[TBL] [Abstract][Full Text] [Related]
5. BDNF over-expression induces striatal serotonin fiber sprouting and increases the susceptibility to l-DOPA-induced dyskinesia in 6-OHDA-lesioned rats.
Tronci E; Napolitano F; Muñoz A; Fidalgo C; Rossi F; Björklund A; Usiello A; Carta M
Exp Neurol; 2017 Nov; 297():73-81. PubMed ID: 28757258
[TBL] [Abstract][Full Text] [Related]
6. Serotonergic nerve fibers in L-DOPA-derived dopamine release and dyskinesia.
Nevalainen N; Af Bjerkén S; Gerhardt GA; Strömberg I
Neuroscience; 2014 Feb; 260():73-86. PubMed ID: 24361918
[TBL] [Abstract][Full Text] [Related]
7. NLX-112, a novel 5-HT1A receptor agonist for the treatment of L-DOPA-induced dyskinesia: Behavioral and neurochemical profile in rat.
Iderberg H; McCreary AC; Varney MA; Kleven MS; Koek W; Bardin L; Depoortère R; Cenci MA; Newman-Tancredi A
Exp Neurol; 2015 Sep; 271():335-50. PubMed ID: 26037043
[TBL] [Abstract][Full Text] [Related]
8. Serotonergic modulation of receptor occupancy in rats treated with L-DOPA after unilateral 6-OHDA lesioning.
Nahimi A; Høltzermann M; Landau AM; Simonsen M; Jakobsen S; Alstrup AK; Vang K; Møller A; Wegener G; Gjedde A; Doudet DJ
J Neurochem; 2012 Mar; 120(5):806-17. PubMed ID: 22117574
[TBL] [Abstract][Full Text] [Related]
9. Buspirone requires the intact nigrostriatal pathway to reduce the activity of the subthalamic nucleus via 5-HT1A receptors.
Sagarduy A; Llorente J; Miguelez C; Morera-Herreras T; Ruiz-Ortega JA; Ugedo L
Exp Neurol; 2016 Mar; 277():35-45. PubMed ID: 26687972
[TBL] [Abstract][Full Text] [Related]
10. Effect of selective serotonin reuptake inhibitors via 5-HT1A receptors on L-DOPA-induced rotational behavior in a hemiparkinsonian rat model.
Inden M; Abe M; Minamino H; Takata K; Yoshimoto K; Tooyama I; Kitamura Y
J Pharmacol Sci; 2012; 119(1):10-9. PubMed ID: 22510520
[TBL] [Abstract][Full Text] [Related]
11. 5-Hydroxy-tryptophan for the treatment of L-DOPA-induced dyskinesia in the rat Parkinson's disease model.
Tronci E; Lisci C; Stancampiano R; Fidalgo C; Collu M; Devoto P; Carta M
Neurobiol Dis; 2013 Dec; 60():108-14. PubMed ID: 24004632
[TBL] [Abstract][Full Text] [Related]
12. Increased L-DOPA-derived dopamine following selective MAO-A or -B inhibition in rat striatum depleted of dopaminergic and serotonergic innervation.
Sader-Mazbar O; Loboda Y; Rabey MJ; Finberg JP
Br J Pharmacol; 2013 Nov; 170(5):999-1013. PubMed ID: 23992249
[TBL] [Abstract][Full Text] [Related]
13. Diverse serotonin actions of vilazodone reduce l-3,4-dihidroxyphenylalanine-induced dyskinesia in hemi-parkinsonian rats.
Meadows SM; Conti MM; Gross L; Chambers NE; Avnor Y; Ostock CY; Lanza K; Bishop C
Mov Disord; 2018 Nov; 33(11):1740-1749. PubMed ID: 30485908
[TBL] [Abstract][Full Text] [Related]
14. Acute L-DOPA administration reverses changes in firing pattern and low frequency oscillatory activity in the entopeduncular nucleus from long term L-DOPA treated 6-OHDA-lesioned rats.
Aristieta A; Ruiz-Ortega JA; Morera-Herreras T; Miguelez C; Ugedo L
Exp Neurol; 2019 Dec; 322():113036. PubMed ID: 31425688
[TBL] [Abstract][Full Text] [Related]
15. The novel 5-HT1A receptor agonist, NLX-112 reduces l-DOPA-induced abnormal involuntary movements in rat: A chronic administration study with microdialysis measurements.
McCreary AC; Varney MA; Newman-Tancredi A
Neuropharmacology; 2016 Jun; 105():651-660. PubMed ID: 26777281
[TBL] [Abstract][Full Text] [Related]
16. Zonisamide attenuates the severity of levodopa-induced dyskinesia via modulation of the striatal serotonergic system in a rat model of Parkinson's disease.
Tohge R; Kaneko S; Morise S; Oki M; Takenouchi N; Murakami A; Nakamura M; Kusaka H; Yakushiji Y
Neuropharmacology; 2021 Oct; 198():108771. PubMed ID: 34474045
[TBL] [Abstract][Full Text] [Related]
17. Characterization of enhanced behavioral responses to L-DOPA following repeated administration in the 6-hydroxydopamine-lesioned rat model of Parkinson's disease.
Henry B; Crossman AR; Brotchie JM
Exp Neurol; 1998 Jun; 151(2):334-42. PubMed ID: 9628768
[TBL] [Abstract][Full Text] [Related]
18. Antidyskinetic effect of A2A and 5HT1A/1B receptor ligands in two animal models of Parkinson's disease.
Pinna A; Ko WK; Costa G; Tronci E; Fidalgo C; Simola N; Li Q; Tabrizi MA; Bezard E; Carta M; Morelli M
Mov Disord; 2016 Apr; 31(4):501-11. PubMed ID: 26871939
[TBL] [Abstract][Full Text] [Related]
19. Role of 5-HT1A Receptor in Vilazodone-Mediated Suppression of L-DOPA-Induced Dyskinesia and Increased Responsiveness to Cortical Input in Striatal Medium Spiny Neurons in an Animal Model of Parkinson's Disease.
Altwal F; Padovan-Neto FE; Ritger A; Steiner H; West AR
Molecules; 2021 Sep; 26(19):. PubMed ID: 34641332
[TBL] [Abstract][Full Text] [Related]
20. Effects of prolonged selective serotonin reuptake inhibition on the development and expression of L-DOPA-induced dyskinesia in hemi-parkinsonian rats.
Conti MM; Ostock CY; Lindenbach D; Goldenberg AA; Kampton E; Dell'isola R; Katzman AC; Bishop C
Neuropharmacology; 2014 Feb; 77():1-8. PubMed ID: 24067924
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
